Netherlands Cancer Institute (NKI)
Division of Cell Biology II
Chemical Biology Laboratory, B6
Plesmanlaan 121
1066 CX Amsterdam, The Netherlands
latest news
- Publication on active-site directed probes in...2013, February 06On terminal alkynes that can react with ac...
read more » - Launch of UbiQ-PEP™: custom ubiquitinated p...2013, February 06Our UbiQ-PEP™ service provides ...
read more »
overview technologies
Our technology platform consists of three proprietary technologies, UbiQ-Block™, UbiQ-Click™ and UbiQ-Syn™, which allow us to develop unique products and services that have been lacking in the ubiquitin (Ub) field. With these chemical synthesis technologies we can construct any Ub conjugate, Ub mutant and combinations thereof. ...
read more »
goal and mission statement
We develop and commercialize ubiquitin research tools, enabling drug discovery in the rapidly expanding ubiquitin-based field. Our products are targeted at Pharma companies and academic research labs. Next to our reagent business, we develop specific HTS assays and we conduct HTS DUB inhibitor programs, both for internal development as well as partnered with Pharma.